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Whole exome sequencing (WES) has proven an effective tool for the discovery of 
genetic defects in patients with primary immunodeficiencies (PIDs). However, success in 
dissecting the genetic etiology of common variable immunodeficiency (CVID) has been 
limited. We outline a practical framework for using WES to identify causative genetic 
defects in these subjects. WES was performed on 50 subjects diagnosed with CVID 
who had at least one of the following criteria: early onset, autoimmune/inflammatory 
manifestations, low B lymphocytes, and/or familial history of hypogammaglobulinemia. 
Following alignment and variant calling, exomes were screened for mutations in 269 PID-
causing genes. Variants were filtered based on the mode of inheritance and reported 
frequency in the general population. Each variant was assessed by study of familial 
segregation and computational predictions of deleteriousness. Out of 433 variations 
in PID-associated genes, we identified 17 probable disease-causing mutations in 15 
patients (30%). These variations were rare or private and included monoallelic mutations 
in NFKB1, STAT3, CTLA4, PIK3CD, and IKZF1, and biallelic mutations in LRBA and 
STXBP2. Forty-two other damaging variants were found but were not considered likely 
disease-causing based on the mode of inheritance and/or patient phenotype. WES 
combined with analysis of PID-associated genes is a cost-effective approach to identify 
disease-causing mutations in CVID patients with severe phenotypes and was successful 
in 30% of our cohort. As targeted therapeutics are becoming the mainstay of treatment 
for non-infectious manifestations in CVID, this approach will improve management of 
patients with more severe phenotypes.
Keywords: common variable immunodeficiency, whole exome sequencing, next-generation sequencing, primary 
immunodeficiencies, genetic diagnosis
Abbreviations: CADD, combined annotation-dependent depletion; CVID, common variable immunodeficiency; MSC, muta-
tion significance cutoff; NGS, next-generation sequencing; WES, whole exome sequencing; WGS, whole genome sequencing.
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inTrODUcTiOn
Common variable immunodeficiency (CVID) is the most 
common symptomatic group of known primary immunodefi-
ciency (PID) syndromes, affecting approximately 1 in 25,000 
people (1). This diagnosis is characterized by decreased IgG 
and either low IgA or IgM, absent or deficient specific antibody 
responses to infection or vaccination, and exclusion of other 
causes of hypogammaglobulinemia (1). Patients with CVID 
commonly have a history of sinopulmonary infections, but over 
half experience other complications, including autoimmunity, 
interstitial lung disease, lymphoid hyperplasia, inflammatory 
bowel disease, nodular regenerative hyperplasia of the liver, 
granulomatous infiltrations, or malignancy (2). The clinical 
heterogeneity, combined with a variable age of onset, suggests 
that this syndrome is a collection of clinical entities caused by a 
number of distinct genetic defects. Genetic analyses of subjects 
with a CVID phenotype have identified recessively inherited 
traits with biallelic mutations in ICOS, CD19, CD20, CD21, 
CD81, PRKCD, and LRBA, and autosomal dominant traits with 
monoallelic mutations in PIK3CD, NFKB2, PIK3R1 (1), and, 
most recently, NFKB1 (3) and, as we have shown, IKZF1 (4). In 
addition, hypomorphic mutations in genes whose null mutations 
are associated with severe combined immune deficiency have 
been identified in rare CVID cases (5), illustrating the broad 
phenotypic spectrum of mutations at these loci.
Whole exome sequencing (WES) has proven an effective tool 
for the discovery of mutations in novel PID-causing genes in 
patients with syndromes of unknown etiology (6). WES can also 
help reach a diagnosis in unknown genetic disorders. A recent 
observational study of exome-sequenced patients with suspected 
genetic disorders reported a molecular diagnosis rate of approxi-
mately 25% (7). In this approach, sequenced exomes are aligned 
with reference genomes, allowing identification of disease-related 
mutations. Candidate variations are then screened through 
databases that provide information on allele frequency, allowing 
elimination of mutations that do not match disease occurrence 
or the predicted method of inheritance. Despite the success of 
next-generation sequencing (NGS), the best approach for genetic 
diagnosis in patients with the CVID syndrome has been unclear 
since selection of patients, insurance reimbursement policies, 
and, most importantly, the complexity of variant analysis are 
obvious hurdles. The goal of this study is to outline a practical 
approach for clinicians seeking to diagnose genetic defects lead-
ing to more severe CVID phenotypes. We report here the findings 
of WES of 50 selected CVID patients combined with a targeted 
screening approach to identify pathogenic mutations in genes 
known to cause PIDs.
MaTerials anD MeThODs
Patient selection
Subjects were diagnosed with CVID using established criteria, 
including serum IgG and IgA and/or IgM deficiency with 
proven loss of antibody production (1) and enrolled in a Mount 
Sinai institutional review board-approved protocol for this 
study. The subjects selected for WES met one or more of the 
following criteria: early-onset of manifestations (under age 10) 
(36%),  autoimmune/inflammatory manifestations (76%), low 
B  lymphocyte counts (58%), and/or familial history of hypogam-
maglobulinemia (16%). Male subjects with known causes of 
absent B cells (X-linked agammaglobulinemia) were excluded. 
In contrast to previous reports, which have described autosomal 
recessive variants, no subjects in this report had a background 
suggestive of consanguinity. When available, samples from 
parents and siblings of CVID patients were submitted for whole 
exome and/or Sanger sequencing to study familial segregation.
Whole exome sequencing
Genomic DNA was extracted from peripheral blood mono-
nuclear cells and sheared with a Covaris S2 Ultrasonicator. 
An adaptor-ligated library was prepared with the Paired-End 
Sample Prep kit V1 (Illumina). Exome capture was performed 
with the SureSelect Human All Exon kit (Agilent Technologies). 
Massively parallel sequencing was performed on a HiSeq 2500 
(Illumina), which generates 100-base reads. Sequences were 
aligned for variant calling and annotation with the human 
genome reference sequence (hg19 build) using BWA aligner 
(8). Downstream processing was performed with the genome 
analysis toolkit (GATK) (9), SAMtools (10), and Picard Tools 
(http://picard.sourceforge.net/). A GATK UnifiedGenotyper and 
a GATK IndelGenotyperV2 were used to identify substitution 
and indel variant calls, respectively. Calls with a read coverage 
of ≤2× and a Phred-scaled SNP quality of ≤20 were filtered out. 
All variants were annotated with the GATK Genomic Annotator 
(Broad Institute).
Targeted gene screening
Patient exomes were filtered for mutations in 269 genes associ-
ated with PIDs (Table S1 in Supplemental Material). Heterozygous 
and homozygous mutations were excluded if the allele frequen-
cies in the general population were >0.01 and 1.0%, respectively, 
in the Exome Aggregation Consortium database (ExAC, Broad 
Institute). Top likely disease-causing candidates were Sanger 
sequenced for confirmation (primers in Table S2 in Supplemental 
Material). Familial segregation was studied when samples were 
available. Other candidate mutations were confirmed by examin-
ing read alignment in the integrated genomics viewer (IGV; Broad 
Institute). All confirmed mutations were subsequently analyzed 
using computational predictors of mutation severity, including 
combined annotation-dependent depletion (CADD) (11), and 
were compared with the gene-specific mutation  significance 
cutoff (MSC) (12). Variants with CADD scores below the gene-
specific MSC were excluded. Confirmed variations were also 
screened through the Human Gene Mutation Database (13) to 
identify published disease-associated variations.
resUlTs
Our cohort of 50 patients included 42 sporadic and 8 familial 
cases. The familial cases included two sisters, two brothers, father 
and son, and two second cousins. The average age of patients was 
36 years, and 54% of patients were females. Following sequence 
alignment and variant calling, patient exomes were filtered 
TaBle 1 | Monoallelic mutations.
Patient gene refseq transcript coding change Protein change caDD exac freq
1 NFKB1 NM_003998.3 c.1301-1G > A 24 –
2 c.1301-1G > A 24 –
3 c.259-4A > G 9.635 0.000008256a
4 c.957T > A p.Y319* 36 –
5 c.1375delT p.F459Lfs*26 23.2 –
6 STAT3 NM_139276.2 c.737G > A p.R246Q 33 –
7 c.937T > C p.F313L 16.66 –
8 c.307C > T p.R103W 34 –
9 CTLA4 NM_005214.4 c.56_57insCTGG p.T19Tfs*42 19.5 –
10 c.406C > G p.P136A 23.8 –
11 PIK3CD NM_005026.3 c.3061G > A p.E1021Kb (16) 31 –
12 IKZF1 NM_006060.5 c.551G > A p.R184Q 27.9 –
aVariant reported in a single patient in the ExAC database.
bPublished disease-causing variant.
FigUre 1 | Filtering strategy for Wes and the 269 PiD gene screen. 
Includes sequencing data for all 50 patients, of which 38 were found to have 
mutations in PID-associated genes. Novel variants were those not reported in 
ExAC, whereas rare variants were reported with a frequency of <0.1% 
(heterozygous) or 1.0% (homozygous).
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to identify significant mutations in 1 or more of 269 immune 
deficiency-related genes (Table S1 in Supplemental Material). 
This approach revealed 433 variations in 38 patients (76% of 
the cohort), of which 64 (in 38 genes) were either private or rare 
(Figure 1). Seventy-two percent of these variations are estimated 
to be in the top 1% of all human hg19 reference SNVs (CADD-
scaled score ≥20) and 20% in the top 0.1% (CADD-scaled score 
≥30). Eleven have been published as disease-causing or -associ-
ated. Of the 64 private or rare variations identified, 17 (Tables 1 
and 2) were considered likely disease-causing in 15 patients (30%) 
(Figure 2; Tables 3 and 4). We also noted 5 variants in 8 patients 
in TNFRSF13B (Tables S3 and S4 in Supplementary Material), 
which is known to be weakly associated with CVID (14), and 42 
variants in other genes associated with PIDs (Tables S5 and S6 in 
Supplementary Material).
Monoallelic Mutations
Five patients were identified with mutations in NFKB1, which 
encodes the NF-κB1 p105 subunit that is processed into the 
active p50 transcription factor (15). Three patients were sporadic 
cases, while two were second cousins. The mutations in NFKB1 
included two nucleotide substitutions that may affect splicing 
(c.1301-1G > A in the related patients 1 and 2; c.259-4A > G in 
patient 3), one nonsense mutation (p.Y319* in patient 4), and 
one frameshift deletion (p.F459Lfs*26 in patient 5) (Table  1). 
Three of these variations are novel and none have been previ-
ously described as disease-causing. All five patients initially 
had profound hypogammaglobulinemia and various degrees of 
autoimmune and inflammatory manifestations, and four patients 
were diagnosed with opportunistic infections (Table 3). Despite 
immunoglobulin replacement, two patients (#2 and 4) did not 
survive.
We also identified novel mutations in STAT3 (Table  1) in 
three unrelated patients who had a history of autoimmune 
cytopenias and granulomatous organ infiltration (Table 3). The 
variant in patient 6 (p.R246Q) is de novo, while the mutation 
in patient 7 (p.F313L) was inherited from his unaffected father. 
Patient 8 shares her mutation (p.R103W) with her mother and 
two siblings, suggesting incomplete penetrance. Two unrelated 
patients with low B cells and severe autoimmunity had novel 
mutations in the regulatory receptor CTLA4 gene. One of these 
mutations, p.T19Tfs*42, was identified in both patient 9 and her 
asymptomatic mother, also suggesting incomplete penetrance, 
while the other, p.P136A, in patient 10 was de novo. In one 
patient (#11) with recurrent sinopulmonary infections and severe 
pulmonary and gastrointestinal manifestations, we identified 
the gain-of-function substitution p.E1021K in PIK3CD, a gene 
which codes for p110δ, the catalytic subunit of phosphoinositide 
3-kinase δ (PI3Kδ) (16). Finally, we also noted an amino acid 
substitution (p.R184Q) in patient 12 in IKZF1, which codes for 
the hematopoietic zinc finger transcription factor IKAROS (17). 
This patient exhibited agammaglobulinemia with the absence of 
B cells and recurrent pneumonias starting at the age of 9. Her 
mother, who is mildly hypogammaglobulinemic, shares this 
mutation, suggesting variable expressivity. Patient 12 is included 
in a report demonstrating that the p.R184Q mutation and others 
are deleterious to the ability of IKAROS to bind its consensus 
sequence and properly localize in the nucleus (4).
Biallelic Mutations
Two unrelated adult patients with sporadic CVID, granulomatous 
disease, and autoimmune cytopenias (Table 4) had mutations in 
FigUre 2 | Percentages of patients with likely disease-causing  
or -associated mutations. One patient had mutations in both PIK3CD and 
TNFRSF13B but was only included in the PIK3CD category. The Unknown 
category contains both patients for whom no variations in PID-associated 
genes were found (n = 12) and those who were found only to have a 
mutation reported in Table S5 in Supplementary Material (n = 16).
TaBle 2 | Biallelic mutations.
Patient gene refseq transcript coding change Protein change caDD exac freq
13 LRBA NM_006726.4 c.1399A > G p.M467V 19 0.002165
c.8351C > G p.A2784G 25.7 –
14 c.2674G > A p.A892T 24.4 0.001532
c.6695T > C p.I2232T 27.9 0.0002160
15 STXBP2 NM_006949.3 c.474_483delinsGA p.C158Wfs*78a (27) 33 –
c.1001C > T p.P334La (27) 23.4 0.00004944
aPublished disease-causing variant.
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LRBA, a protein implicated in regulation of cell survival (18), 
endosomal trafficking (19), and regulation of CTLA4 (20). The 
four mutations (p.M467V and p.A2784G in patient 13; p.A892T 
and p.I2232T in patient 14) are rare or novel and have not been 
previously associated with clinical disease (Table 2). Although the 
CADD scores for these mutations fall below the MSC for LRBA, we 
include them as the patient phenotypes closely match previously 
reported cases (19, 21). Sanger sequencing of parents revealed 
that the patients are compound heterozygous for these variants. 
Compound heterozygous mutations in STXBP2 (p.C158Wfs*78 
and p.P334L) were also identified in one patient (#15) who had 
very low B cells and a prior severe EBV infection associated with 
neutropenia that responded to corticosteroids, cyclosporine, and 
filgrastim. STXBP2, which encodes syntaxin-binding protein 2, 
has a role in cytotoxic T and NK cell functions and is associated 
with familial hemophagocytic lymphohistiocytosis (FHL), a clini-
cal phenotype not found in this patient (22). Sanger sequencing 
indicated that the patient inherited one STXBP2 mutation from 
each parent.
Mutations in TnFrsF13B (Taci)
As in previous reports in CVID, we identified known variations in 
TNFRSF13B, which codes for transmembrane activator and cal-
cium-modulating cyclophilin ligand interactor (TACI). Although 
some of these variations occur at a frequency greater than our 
specified cutoff, we included them as validation for our cohort, 
as TNFRSF13B mutations have been identified in approximately 
10% of CVID patients (14). These variations occurred in eight 
patients and include one unreported mutation in a single patient 
(#11) who also had the p.E1021K substitution in PIK3CD (Tables 
S3 and S4 in Supplementary Material). All TNFRSF13B variations 
were monoallelic except for patient 20, whose variations are bial-
lelic as determined by WES of siblings.
Other Damaging Mutations
We also identified 42 other heterozygous mutations (Table 
S5 in Supplementary Material) in our patients (Table S6 in 
Supplementary Material). A majority of these variants (n = 30) 
have been previously reported in ExAC and, of those, four have 
already been published as disease-causing (noted in Table S5 
in Supplementary Material). In addition, CADD scores for all 
variants included in Table S5 in Supplementary Material exceed 
their gene-specific MSC. However, they were not considered 
to be likely disease-causing in our patients since the deficiency 
caused by variations in the gene did not match the phenotype 
of the patient and/or the zygosity of the mutation in the patient 
did not match the published inheritance pattern for the disease. 
Of note, we identified two mutations in DOCK8 (p.R1008Q and 
p.E1104D) in patient 19. Family studies indicated that both these 
mutations were inherited from the patient’s father, who is healthy. 
Though the mutations are predicted to be highly damaging by 
CADD, the patient demonstrated recurrent sinopulmonary 
infections and severe granulomatous infiltrations but no cardinal 
manifestations of DOCK8 deficiency (23). We also found one 
variant in FASLG (p.R198W) in two sisters (patients 27 and 28) 
with recurrent pneumonias and low B cells. Interestingly, three 
unrelated patients (#24, 32, and 33) carry a damaging heterozy-
gous variant (p.R1305H) in LRBA. All three patients had recurrent 
sinopulmonary infections, and two shared notable organomegaly, 
hepatic nodular regenerative hyperplasia, and autoimmune cyto-
penias. Copy number variation in these patients has not yet been 
explored.
DiscUssiOn
While CVID has long been considered a clinically heterogeneous 
group of PIDs (1), the gene defects that underlie this complex 
syndrome have been difficult to identify, particularly in non-
familial cases. In this study, we collected complete exome data 
for 50 selected CVID subjects, most of whom were sporadic, who 
had severe phenotypes found in about half of all CVID cases (2). 
TaBle 3 | clinical and immunological phenotypes of patients with monoallelic mutations.
Patient sex age/age 
at onset 
(years)
infections Other conditions igg  
(7.00–
16.00 g/l)a
iga  
(0.70–
4.00 g/l)a
igM  
(0.40–
2.30 m/l)a
cD3+ 
(750–2500/
mm3)a
cD4+ 
(480–1700/
mm3)a
cD8+ 
(180–1000/
mm3)a
cD3−cD56+ 
(135–525/
mm3)a
cD19+  
(75–375/mm3)a/
cD19+cD27+igD−%b
NFKB1
1c M Died at 
51/42
Pneumonias; chronic 
sinusitis; conjunctivitis; 
otitis; shingles
Lung granulomas; 
enteropathy; lymphoid 
hyperplasia; neutropenia; 
hypersplenism (s/p 
splenectomy); aphthous 
ulcers
Txd <0.07 (↓) <0.11 (↓) 378 (↓) 268 (↓) 117 (↓) 50 (↓) 7 (↓)/0
2c F 33/19 Chronic sinusitis; 
pneumonias; 
conjunctivitis; shingles; 
otitis; C. difficile colitis
Morphea <0.51 (↓) <0.05 (↓) <0.05 (↓) 1428 1007 435 53 (↓) 21 (↓)/NA
3 M 48/21 Pneumonias; empyema 
(s/p lobectomy); chronic 
sinusitis
Bronchiectasis; vitiligo, 
hypothyroidism
Txd <0.01 <0.05 (↓) 682 (↓) 323 (↓) 336 45 (↓) 62 (↓)/0
4 F Died at 
48/19
MAI; Pneumocystis 
jirovecii pneumonia; lung 
abcesses; PML (cause 
of death)
ITP (s/p splenectomy); 
AIHA; aplastic bone marrow
Txd 0.07 (↓) 0.17 (↓) NA 1177 589 NA 0 (↓)/0
5 F 25/7 Pneumonias, otitis; 
giardiasis; C. difficile 
colitis; HSV infection; 
cellulitis; MAI
Bronchiectasis, enteropathy; 
osteopenia; poor growth
Txd 0.02 0.02 (↓) 473 (↓) 518 (↓) 153 (↓) 98 (↓) 0 (↓)/0.06
sTaT3
6 F 55/11 Brain abscess; West Nile 
virus encephalitis
Liver and lung granulomas; 
ITP; hepatopulmonary 
syndrome; Severe arthritis; 
AIHA (s/p splenectomy), 
hemorragic stroke; DVT; 
hypothyroidism
0.60 (↓) 0.07 (↓) 0.20 (↓) 2223 1254 902 170 562 (↑)/0
7 M 18/3 Molluscum contagiosum; 
Staphylococcus 
infections; tinea corporis; 
C. difficile colitis
Type 1 diabetes; ITP/Evans 
syndrome hypothyroidism; 
short stature
6.81 (↓) <0.07 (↓) 0.37 715 (↓) 337 (↓) 276 83 (↓) 401/NA
8 F 18/5 Molluscum contagiosum Microscopic colitis; 
ITP, granulomatous 
lung disease; lymphoid 
hyperplasia; pure red cell 
aplasia; atopic dermatitis; 
malabsorption
3.40 (↓) 0.08 (↓) 0.20 (↓) 1180 641 432 92 (↓) 237/NA
cTla4
9 F 17/1 Conjunctivitis; warts Inflammatory bowel disease; 
LIP, ITP; AIHA, autoimmune 
neutropenia; erythema 
nodosum; failure to thrive; 
osteoporosis
5.94 (↓) <0.05 (↓) 0.08 (↓) 756 (↓) 477 234 (↓) 83 (↓) 93 (↓)/2.51
(Continued)
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TaBle 4 | clinical and immunological phenotypes of patients with biallelic mutations.
Patient sex Year of 
birth/age 
at onset 
(years)
infections Other conditions igg  
(7.00–
16.00 g/l)a
iga  
(0.70–
4.00 g/l)a
igM  
(0.40–
2.30 g/l)a
cD3+ 
(750–2500/
mm3)a
cD4+ 
(480–1700/
mm3)a
cD8+ 
(180–1000/
mm3)a
cD3-cD56+ 
(135–525/
mm3)a
cD19+  
(75–375/mm3)a/
cD19+cD27+igD−%b
LRBA
13 F Died at 
39/25
Cellulitis; pneumonias Liver and pulmonary 
granulomas leading to 
organ failures (cause of 
death); ITP; splenectomy
5.56 (↓) <0.07 (↓) 0.17 (↓) 2995 1579 1479 363 4 (↓)/0
14 M Died at 
56/36
Fulminant; mycoplasma 
infection; recurrent 
bronchitis
Lung granuloma; AIHA, 
ITP; squamous-cell 
carcinoma of the mouth
1.72 (↓) <0.07 (↓) 0.06 (↓) 764 331 (↓) 411 19 (↓) 0 (↓)/0
STXBP2
15 M 35/28 EBV age 28 with 
neutropenia; recurrence 
of EBV at age 34; recurrent 
sinusitis; shingles ×2
IBD 0.81 (↓) <0.05 (↓) <0.05 (↓) 1623 1250 304 32 (↓) 9 (↓)/0
AIHA, autoimmune hemolytic anemia; EBV, Epstein–Barr virus; IBD, inflammatory bowel disease; ITP, immune thrombocytopenic purpura.
aNormal value ranges in patients aged six or more.
bPercentage of total CD19+ cells.
TaBle 3 | continued
Patient sex age/age 
at onset 
(years)
infections Other conditions igg  
(7.00–
16.00 g/l)a
iga  
(0.70–
4.00 g/l)a
igM  
(0.40–
2.30 m/l)a
cD3+ 
(750–2500/
mm3)a
cD4+ 
(480–1700/
mm3)a
cD8+ 
(180–1000/
mm3)a
cD3−cD56+ 
(135–525/
mm3)a
cD19+  
(75–375/mm3)a/
cD19+cD27+igD−%b
10 M 24/14 Molluscum contagiosum; 
influenza A; otitis media; 
recurrent sinusitis, 
bronchitis, and otitis 
media
Follicular bronchiolitis; 
kidney, lung, and lymph 
node granulomas; ITP/AIHA
3.10 (↓) 0.22 (↓) 3.87 (↑) 877 457 410 140 7 (↓)/0.3
PiK3cD
11 F 16/3 Chronic otitis media; 
pneumonias; sinusitis; 
periorbital cellulitis; HSV 
infection; conjunctivitis; 
Giardiasis
Chronic colitis with 
malabsorption and short 
stature; ILD; nodular 
hyperplasia; osteoporosis; 
splenomegaly
5.84 (↓) <0.11 (↓) 5.87 (↑) 1033 278 (↓) 594 186 388/0.65
iKZF1
12 F 26/9 Recurrent pneumonias 0.42 (↓) <0.01 (↓) 0.07 (↓) 3388 1416 1888 128 (↓) <1 (↓)/NA
AIHA, autoimmune hemolytic anemia; DVT, deep venous thrombosis; HSV, herpes simplex virus; ILD, interstitial lung disease; ITP, immune thrombocytopenic purpura; LIP, lymphocytic interstitial pneumonia; NA, not available; MAI, 
Mycobacterium avium intracellulare; PML, progressive multifocal leukoencephalopathy.
aNormal value ranges in patients aged six or more.
bPercentage of total CD19+ cells.
cPatients 1 and 2 are second cousins.
dPatients were already on IgG replacement therapy when evaluated for the first time in our center.
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Our goal was to identify variants leading to these manifestations, 
filtering first for a panel of causative genes. The filtering results 
demonstrated likely disease-causing mutations in NFKB1, STAT3, 
CTLA4, PIK3CD, IKZF1, LRBA, and STXBP2 in 15 patients (30%) 
and disease-associated mutations in TNFRSF13B in 8 patients 
(16%) (Figure 2). Our findings indicate that seeking pathogenic 
PID mutations in sporadic CVID is a fruitful approach. While 
eight subjects were familial cases of CVID, the same damaging 
variant was noted in only two of these subjects (second cousins), 
illustrating that additional genes leading to familial B cell defects 
remain unidentified.
Private or rare heterozygous mutations were identified in three 
transcription factors (NFKB1, STAT3, and IKZF1) and two sign-
aling proteins (CTLA4 and PIK3CD). Mutations in four genes, 
NFKB1, STAT3, CTLA4, and PIK3CD, led to not only profound 
B cell defects but also significant immune dysregulation, includ-
ing autoimmunity, lymphoid hyperplasia, and organ infiltrative 
granulomatous disease, complications described in other subjects 
with familial inheritance (3, 16, 24, 25). In our patients, mutations 
in NFKB1 and STAT3 also led to opportunistic infections, includ-
ing Mycobacterium avium intracellulare, JC virus-induced pro-
gressive multifocal leukoencephalopathy, Pneumocystis jirovecii 
pneumonia, and Molluscum contagiosum. In contrast, the IKZF1 
mutation found in one patient led to near agammaglobulinemia 
and bacterial infections but no evidence of immune dysregulation 
or susceptibility to additional organisms (4). While two related 
CVID patients had the same NFKB1 variant, one healthy family 
member of those patients and healthy family members of subjects 
with STAT3 and CTLA4 mutations were found to have the same 
variants, illustrating the variable penetrance of monoallelic vari-
ations in these genes, as previously reported (3, 25, 26). However, 
the STAT3 variants p.F313L and p.R103W found in patients 7 
and 8 possess gain-of-function properties and have been identi-
fied in other confirmed cases of early onset autoimmune disease, 
validating the pathogenic roles of these mutations in our patients 
(Vogel and Cooper, personal communication).
Compound heterozygous mutations were also identified 
in three subjects with sporadic disease. Of these, two patients 
with profound B cell defects, autoimmunity, and granulomatous 
disease had novel mutations in LRBA and died in middle age of 
organ damage. Homozygous mutations in this gene have previ-
ously been associated with severe CVID phenotypes associated 
with loss of regulatory T-cell functions (19, 21). Here, we found 
patients with apparently adult-onset CVID and no family history 
who exhibited a similar severe phenotype. Another patient with 
hypogammaglobulinemia, inflammatory bowel disease, and a 
history of EBV infection had compound heterozygous mutations 
in STXBP2. However, he never displayed hemophagocytosis, gen-
erally associated with STXBP2 mutations (22). A previous report 
described a patient with severe FHL requiring hematopoietic 
stem cell transplant who had the same two STXBP2 mutations, 
indicating that these are likely to be deleterious (27). The reason 
for the discordance between our patient’s phenotype, with a 
predominant B cell defect, and the previously reported cases is 
unknown.
In addition to the genes identified that are associated with 
loss of antibody function and inflammatory complications, we 
also identified rare or novel monoallelic variants that, in other 
patients, are known to cause different immune deficiency syn-
dromes. These include the p.W688* mutation in CIITA in patient 
3, previously reported in a patient with a compound heterozygous 
MHC Class II deficiency (28), and the p.R1445Q substitution 
in LRBA in patient 2, which led to loss of CTLA4 and immune 
dysregulation in a patient when biallelic (20). Curiously, we also 
noted a p.R1305H substitution in LRBA in three other unrelated 
patients. The impact of such heterozygous mutations on immune 
functions in these and similar subjects is unclear.
Using whole genome sequencing, van Schouwenburg et  al. 
recently published results for 31 sporadic CVID patients in which 
they identified 112 variants (38 novel) in pathways that could lead 
to CVID-like antibody failure (29). In contrast to our study, the 
CVID patients examined in this report were not pre-selected 
based on the severity of clinical and/or immunological pheno-
types. When applying our filtering criteria, none of the variants 
described in their study would be considered likely causative of 
CVID. In our study, pre-selection of subjects with more severe 
non-infectious complications most likely contributed to identifi-
cation of novel and rare pathogenic mutations.
Family studies in cohorts have been enormously valuable 
for exploring the pathogenesis of CVID, revealing many genes 
essential for B cell development and maintenance (3, 4, 26, 30). 
However, the utility of sequencing single genes or a panel of genes 
in patient populations is limited and not cost-effective. For exam-
ple, in 699 PID subjects, mutations in PIK3CD were identified 
in only 3 siblings with CVID (31). Sequencing panels that are 
commercially available provide an important and indispensable 
alternative to clinicians. Such panels are designed with probes that 
target genes relevant for specific diseases or phenotypes and may 
provide higher coverage and sequencing depth than WES. These 
panels are often appropriate for the genetic diagnosis of PIDs pre-
senting with clear-cut clinical and/or immunological phenotypes 
but, if emerging causative genes are not yet incorporated, subjects 
with CVID, who may have heterogeneous phenotypes, will not be 
diagnosed. Furthermore, gene panels could be more expensive 
than WES are not as easily updated and, in contrast to WES, 
require repeat testing of patient samples as new PID-associated 
genes are described. Combining WES with an expandable PID-
associated gene filter streamlines the search for disease-causing 
variants. The success of NGS also guides physicians toward thera-
peutic approaches that target the deficient or dysregulated protein 
in a patient. Notable examples include utilizing tocilizumab in 
subjects with STAT3 gain-of-function variants (26), CTLA-4-Ig 
fusion protein in subjects with CTLA4 haploinsufficiency or 
LRBA deficiency (20, 32), and rapamycin, which inhibits mTOR 
downstream of PI3K, in patients with gain-of-function PIK3CD 
mutations (33). This approach may be of considerable value 
in CVID subjects with more severe phenotypes, such as those 
examined here.
The use of NGS to identify mutations associated with immu-
nodeficiency diseases has become increasingly common. In a 
recent 5-year period, NGS identified more than 30 new molecular 
etiologies of PIDs (6). Our results also indicate the higher yield 
of WES when targeting CVID patients with severe clinical or 
immunological complications, even those with no family history 
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of immune deficiency. With the pronounced overlap between 
the inflammatory conditions found in CVID, WES followed by 
periodic filtering with an expanding panel of genes may provide a 
practical means for genetic diagnosis of these subjects. However, 
while costs of NGS have dropped substantially in recent years, 
price is still a barrier. Equally important, for most subjects with 
CVID, the relevant genes have not been identified, leading to con-
tinued effort to search for novel genes contributing to the CVID 
phenotype. This is currently ongoing at this and other centers.
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